Naveen Gara, MD
Gastroenterology · San Diego, CANPI 1942406533
Payments from drug & device makers
Across 822 payments — averaging $1853.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$664K
- Takeda Pharmaceuticals U.S.A., Inc.$551K
- Sanofi US Services Inc.$89K
- AbbVie$88K
- Medtronic$46K
- Astrazeneca UK Limited$42K
- plus $44K from 29 others
Across 2 payments — averaging $13,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$27K
What the payments were for
- Consulting fees$74,16042%
- Speaking & faculty fees$81,36546%
- Travel & lodging$10,2636%
- Food & beverage$11,9257%
- Education$3410%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 182 | $664,436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 114 | $551,148 |
| Sanofi US Services Inc. | 7 | $88,681 |
| AbbVie | 271 | $87,732 |
| Medtronic | 33 | $46,129 |
| Astrazeneca UK Limited | 1 | $41,506 |
| Gilead | 53 | $29,052 |
| Ipsen Biopharmaceuticals, Inc | 9 | $5,201 |
| Pfizer | 6 | $3,893 |
| Albireo Pharma, Inc. | 2 | $1,971 |
| Johnson & Johnson | 42 | $1,107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $488 |
| Intercept Pharmaceuticals, Inc. | 17 | $365 |
| Novo Nordisk | 3 | $166 |
| Braintree Laboratories, Inc. | 5 | $161 |
| Phathom Pharmaceuticals, Inc. | 9 | $161 |
| Madrigal Pharmaceuticals | 7 | $147 |
| Celltrion USA Inc. | 6 | $128 |
| Sanofi | 2 | $128 |
| Ferring Pharmaceuticals Inc. | 5 | $109 |
| Bristol Myers Squibb | 6 | $103 |
| Redhill Biopharma Inc. | 4 | $96 |
| Lilly USA, LLC | 1 | $86 |
| Mirum Pharmaceuticals, Inc. | 4 | $84 |
| Echosens North America, Inc. | 1 | $72 |
| Boston Scientific | 3 | $72 |
| Shionogi Inc | 2 | $48 |
| Pentax Of America, Inc. | 2 | $33 |
| Viiv Healthcare Company | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,523,436 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 12 | $308,569 |
| OcalivaObeticholic Acid | 15 | $253,612 |
| XifaxanRifaximin | 12 | $43,455 |
| CreonLipase/Protease/Amylase | 34 | $38,348 |
| LinzessLinaclotide | 56 | $34,835 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 178 | $30,986 |
| ViberziEluxadoline | 13 | $20,297 |
| Dexlansoprazole DrDexlansoprazole | 53 | $16,320 |
| Ursodiol | 73 | $11,207 |
| VoqueznaVonoprazan Fumarate | 15 | $9,471 |
| Pantoprazole Sodium | 1,004 | $8,953 |
| Esomeprazole Magnesium | 80 | $5,091 |
| Nadolol | 30 | $1,801 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 103 | $1,612 |
| CholestyramineCholestyramine (With Sugar) | 11 | $1,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $29,052 | $308,56912 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $365 | $253,61215 claims |
| AbbVieCreon, Linzess, Viberzi | $87,732 | $93,480103 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $488 | $43,45512 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $109 | $30,986178 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $161 | $9,47115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in San Diego
- Brigid BolandSan Diego$2.4M
- William SandbornSan Diego$2.2M
- Michael BennettSan Diego$1.5M
- Taddese DestaSan Diego$1.4M
- Hyun KimSan Diego$1.3M
- Vijayalak PrathaSan Diego$1.2M
- David KunkelSan Diego$679K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.